MESO Q1 2019 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+891.2% YoY

Gross Profit

$7M62.9% margin

Operating Income

-$17M-144.2% margin

Net Income

-$19M-167.6% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+584.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$818,000

Balance Sheet

Total Assets

$689M

Total Liabilities

$161M

Stockholders' Equity

$528M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$1M	+891.2%
Gross Profit	$7M	$297,000	+2364.6%
Operating Income	-$17M	-$20M	+16.4%
Net Income	-$19M	-$7M	-177.7%